Navigation Links
Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Date:11/15/2007

- Trial CL-05 Results Showed Cethromycin had 94.0% Clinical Cure Rate Compared to 93.8% Clinical Cure Rate for Biaxin(R), a Current Standard of

Care Treatment - - Trial CL-05 and Trial CL-06 to Form the Core of New Drug Application -

CHICAGO, Nov. 15 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States. The primary efficacy endpoint of statistical non-inferiority in the clinical cure rate at the test-of-cure visit was achieved. The study results showed that cethromycin cured 94.0% of patients with CAP, compared to Biaxin(R) (clarithromycin), a current standard of care treatment for CAP, which cured 93.8% of studied patients in the per protocol population. In the modified intent to treat population, cethromycin cured 83.1% of patients and Biaxin cured 81.1%. Cethromycin also demonstrated favorable safety results, with reported side effects similar to or less than those seen with Biaxin.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO )

"We are very excited to have met all of our endpoints in Trial CL-05, and we are pleased to have successfully completed the clinical development program of cethromycin. The results attained in this trial, along with the positive results achieved in Trial CL-06 reported in June of this y
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
4. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
6. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)... BASEL, Switzerland, May 15 /- Patie...orld,s most common cancers, can expect,further tre...Herceptin(R),(trastuzumab) following new data that...f Clinical Oncology (ASCO) annual meeting in Chica...s will attend the meeting which,is the premier eve...
(Date:5/15/2008)...Phase II Data Presented at ASCO Showed Acceptable ...ce of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N...emotherapeutic agent eribulin mesylate (E7389) dem...ion of women with locally advanced or metastatic,b...er Phase II clinical,trial. The study also suggest...
(Date:5/15/2008)...ood pressure reductions demonstrated in Blacks, Hi...etes and Obese Individuals, PARSIPPANY, N.J., May...d today that data presented at the American Societ...c Meeting (ASH 2008) in New,Orleans demonstrated t...pine and olmesartan medoxomil) safely and effectiv...
(Date:5/15/2008)... APPENZELL, Switzerland, May 15 /- E...es Food and Drug Administration (FDA) has,granted ...ment of pulmonary,arterial hypertension (PAH). Ter...ivotal Phase II trial in Europe., "The FDA,s gran...encourages and strengthens our development program...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Healthcare Crisis Brought to Life in New TV Show 11337 1Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 1Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 2Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 3CorVel to Present at UBS Global Healthcare Services Conference 11332 1CorVel to Present at UBS Global Healthcare Services Conference 11332 2Gene Plays Jekyll and Hyde Role in Deadly Brain Cancer 11331 1
....5 and 40/25 mg/day and Amlodipine +,Benazepril 5/...of,Hypertension Twenty-Second Annual Scientific Me... -- New data,presented today at the American Socie...ic Meeting (ASH 2007) in Chicago,demonstrated that...n medoxomil/hydrochlorothiazide) was associated wi...
...-May 21, 2007 - Medical,professionals seeking to t...cquired gram-negative pneumonia may have a new wea...ct candidate being,developed by Nektar Therapeutic...rial evaluating the use of,NKTR-061 (Inhaled Amika...h hospital-acquired gram-negative pneumonia were,p...
Other Medicine Technology:Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
(Date:5/16/2008)... - Gefitinib, the once-promising drug formerly app...also known as Iressa, enhanced the effectiveness o...ypes of metastatic breast cancer, according to a P...niversity of Texas M. D. Anderson Cancer Center. ,... first positive study for Iressa in breast cancer,...
(Date:5/16/2008)...ounces appointment of Nomura Code Securities Limit... broker, NEW YORK, May 16 /PRNewswire-FirstCall/ ...estments, Inc. (Amex: MGT ) (the "Company"), and ...Aided Detection (CAD) and,image analysis software ...,of disease, today announced the appointment of NM...
(Date:5/16/2008)...it Portland to Rally Residents to Eat Right, Move ...ts, PORTLAND, Ore., May 16 /PRNewswire/ -- The la...ifferent fad diets -- which seem to go in and out,...ong-term success has been,slim. Two out of three A...ents -- remain overweight or obese., A new campai...
(Date:5/16/2008)...of two proteins in mammalian embryos prevents the ...earchers at the Medical College of Wisconsin, Milw...the May 15 issue of Developmental Biology, was led...gy, neurobiology and anatomy at the Medical Colleg...ly identified the factors responsible for the onse...
Breaking Medicine News(10 mins):Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 2Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 3Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 3Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Medical College of Wisconsin researchers identify proteins that help develop mammalian hearts 2
...ith a common form of brewer's yeast, University of...l functions of a key protein// that allow it to ac...determines gene activity and that, when malfunctio...ous neurological disorders. The work, published in...
... half months after his sexual organ was completely...o lead a normal life again after a Delhi hospital/...e unmarried man from Uttar Pradesh underwent a sev... Sir Ganga Rama Hospital (SGRH), a leading private...
...scientists at Johns Hopkins are making mathematica...ays to perform a surgery.// Surgical tasks such as...illustrated in this model. The team's long-term g...evaluating a surgeon's work and to help doctors im...
...n parliamentarians will attend a two-day conferenc...e's elected representatives in combating the disea...a worldwide network of individual parliamentarians... assembly of Punjab (Pakistan), Pakistan National ...
Other Medicine News:Health News:From a Lowly Yeast, Researchers Divine a Clue to Human Disease 2Health News:Delhi Hospital Reattaches Amputated Penis 2Health News:Robotic Model To Teach Surgical Skills 2Health News:Robotic Model To Teach Surgical Skills 3
... value in high performance electronic pipetting!, ...design reduce hand fatigue and strain , Stress-fre...r coding for easy volume identification , Accepts ...lton AdvanTip Low Retention and AdvanTip Precision...
The Finnpipette BioControl multichannel has the same innovative features as the single channel model.The same universal handle fits all seven multichannel and five single channel tip cone modules. Bo
...s ideal for all liquid handling applications in th...cally-placed operating buttons, and various dispen...erse pipetting and diluting make this a lab favori... a manual pipette without any adverse effects on t...
...vus is so user-friendly that you'll learn how to u...stantly familiar menu and simple button layout, yo...quickly and easily. The large, clear display is ea...ns. The easily accessible two level menu offers t...
Medicine Products: